Connect your AI

MoonLake Immunotherapeutics MLTX PP&E (Net)

PP&E (Net) at other companies

Eli LillyLLY

$26.54B+43.7%

Oruka Therapeutics, Inc.ORKA

$318K+100%

AnaptysBio, Inc.ANAB

$1.28M-26.5%

Opko HealthOPK

$72.59M+2.0%

Cullinan Therapeutics, Inc.CGEM

$342K-43.7%

Aurinia PharmaceuticalsAUPH

$1.99M-22.9%

Segments

By geography

Portugal$948K-22.5%

Switzerland$888K+64.7%

United Kingdom$553K-64.0%

Other financials

Income statement

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Balance sheet

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Cash flow

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Valuation

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Returns & leverage

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is MoonLake Immunotherapeutics's PP&E (net)?: MoonLake Immunotherapeutics (MLTX) reported PP&E (net) of $532K in Q1 2026.
How has MoonLake Immunotherapeutics's PP&E (net) changed year-over-year?: MoonLake Immunotherapeutics's PP&E (net) decreased by 25.2% year-over-year, from $711K to $532K.
What is the long-term trend for MoonLake Immunotherapeutics's PP&E (net)?: Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's PP&E (net) has grown at a 88.5% compound annual growth rate (CAGR), from $45.74K to $577K.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.